☆ 4.6 Article

Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Oncogenic CALR mutant C-terminus mediates dual binding to the thrombopoietin receptor triggering complex dimerization and activation

Nicolas Papadopoulos et al.

Summary: In myeloproliferative neoplasms, frameshift mutants of calreticulin turn into rogue cytokines by inducing constitutive activation of the Thrombopoietin Receptor (TpoR). Here, the authors define how mutant calreticulin acquires specificity for TpoR binding and triggers its constitutive activation.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Hematology

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

Ayalew Tefferi

Summary: Primary myelofibrosis is a stem cell-derived disorder characterized by clonal myeloproliferation, fibrosis, and other symptoms. Diagnosis is made through bone marrow examination and genetic testing. Treatment options mainly involve drug therapy, and new agents are under investigation.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Oncology

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm

Ayalew Tefferi et al.

Summary: Leukemic transformation, or blast-phase MPN, is a serious complication of myeloproliferative neoplasms (MPNs). The incidence of leukemic transformation varies among different MPNs, with estimates ranging from 1-4% for essential thrombocythemia, 3-7% for polycythemia vera, and 9-13% for primary myelofibrosis. Allogeneic hematopoietic stem cell transplant (AHSCT) offers the best chance of long-term survival in MPN-BP, with a 3-year survival rate of over 30%. Pre-transplant bridging chemotherapy, particularly with venetoclax and hypomethylating agent (HMA), may be beneficial in MPN-BP. The optimal pre-and post-transplant measures to improve transplant outcomes require further study.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Cell Biology

Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia

Jiabi Qian et al.

Summary: Through targeted sequencing and high-throughput drug screening, we studied the role of RAS mutations in ALL patients and found that RAS mutations were associated with a higher relapse incidence in children with ALL. Among these mutations, NRAS mutations had a higher leukemogenic potential and might exhibit different responsiveness to inhibition of multiple signaling pathways.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Add to Collection

Review Cell Biology

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives

Julian Baumeister et al.

Summary: Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) are a diverse group of diseases, including ET, PV, PMF, and different subsequent conditions. Progression of the disease can be clinically evident or subclinical, with potential increases in bone marrow fibrosis, driver gene mutational burden, and clonal evolution. The underlying causes of MPN progression are diverse and may involve genetic alterations and chronic inflammation.

CELLS (2021)

Add to Collection

Review Hematology

Functional Consequences of Mutations in Myeloproliferative Neoplasms

Stefan N. Constantinescu et al.

Summary: Driver mutations in JAK2, CALR, and MPL play crucial roles in BCR-ABL1 negative MPNs, leading to persistent JAK2-STAT5 activation. Epigenetic mutations coexist in 35%-40% of MPNs, promoting clonal hematopoiesis and increased fitness of hematopoietic stem cells. Understanding the interactions between driver mutations and epigenetic rewiring is essential for developing better therapeutic interventions for MPNs.

HEMASPHERE (2021)

Add to Collection

Article Oncology

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

Fabio P. S. Santos et al.

LEUKEMIA (2020)

Add to Collection

Letter Hematology

Analysis of saliva samples and cluster of differentiation 3 (CD3)+ lymphocytes as a source of germline DNA in myeloproliferative neoplasms

Nieves Garcia-Gisbert et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

Mira El-Khoury et al.

ONCOGENE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

Elisa Rumi et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Review Hematology

Mutant Calreticulin in the Myeloproliferative Neoplasms

Daniel Prins et al.

HEMASPHERE (2020)

Add to Collection

Review Oncology

RAS-mediated oncogenic signaling pathways in human malignancies

Abdul Q. Khan et al.

SEMINARS IN CANCER BIOLOGY (2019)

Add to Collection

Article Hematology

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Christian Pecquet et al.

BLOOD (2019)

Add to Collection

Article Hematology

Mutant calreticulin in myeloproliferative neoplasms

Joan How et al.

BLOOD (2019)

Add to Collection

Article Biochemistry & Molecular Biology

PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood

Daniel Christoph Amberger et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Review Oncology

A Comparative Analysis of Individual RAS Mutations in Cancer Biology

Carmen Munoz-Maldonado et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Oncology

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients

Ayalew Tefferi et al.

LEUKEMIA (2018)

Add to Collection

Article Oncology

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Ayalew Tefferi et al.

LEUKEMIA (2018)

Add to Collection

Article Medicine, General & Internal

Increased genomic instability following treatment with direct acting anti-hepatitis C virus drugs

Mohamed Tharwat Hegazy et al.

EBIOMEDICINE (2018)

Add to Collection

Article Hematology

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients

Ayalew Tefferi et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Biochemical Research Methods

FATHMM-XF: accurate prediction of pathogenic point mutations via extended features

Mark F. Rogers et al.

BIOINFORMATICS (2018)

Add to Collection

Article Oncology

AACR Project GENIE: Powering Precision Medicine through an International Consortium

Fabrice Andre et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Hematology

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

Ilyas Chachoua et al.

BLOOD (2016)

Add to Collection

Article Hematology

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

Marito Araki et al.

BLOOD (2016)

Add to Collection

Article Genetics & Heredity

dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs

Xiaoming Liu et al.

HUMAN MUTATION (2016)

Add to Collection

Article Oncology

A case of myeloproliferative neoplasm with a normal complete blood cell count: A novel problem of the JAK2 era

Xiu-Peng Ye et al.

ONCOLOGY LETTERS (2016)

Add to Collection

Article Oncology

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

Shannon Elf et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Oncology

Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles

Eejung Kim et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Hematology

Targeted deep sequencing in primary myelofibrosis

Ayalew Tefferi et al.

BLOOD ADVANCES (2016)

Add to Collection

Article Medicine, General & Internal

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Thorsten Klampfl et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Review Hematology

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Jasper H. Smalberg et al.

BLOOD (2012)

Add to Collection

Article Hematology

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia

Jinyong Wang et al.

BLOOD (2010)

Add to Collection

Article Immunology

Hepatitis C Virus Inhibits DNA Damage Repair through Reactive Oxygen and Nitrogen Species and by Interfering with the ATM-NBS1/Mre11/Rad50 DNA Repair Pathway in Monocytes and Hepatocytes

Keigo Machida et al.

JOURNAL OF IMMUNOLOGY (2010)

Add to Collection

Article Hematology

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice

Chaitali Parikh et al.

BLOOD (2006)

Add to Collection

Article Hematology

Implications of NRAS mutations in AML:: a study of 2502 patients

Ulrike Bacher et al.

BLOOD (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.